Drug Discovery
‘We’re not doing 30 bets a year’: Vijay Pande on betting small after running $4B at a16z
Vijay Pande, who left a16z’s roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC, talks about why biology is finally shifting from a “discovery” science to an “engineering” one, why…
















